ASX RELEASE   **19 July 2024**

SECTION 708A NOTICE – ALLOTMENT OF 2,602,758 SHARES

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company") has issued the following fully paid ordinary shares (**Shares**):

a) 1,821,508 Shares issued to senior management (not including any directors) under the Company's Employee Security Ownership Plan on 17 July 2024; and
b) 781,250 Shares issued to a corporate advisor as a fee for services on 19 July 2024.

All of the Shares issued rank pari passu with existing ATX ordinary shares.

In accordance with Section 708A(5)(e) of the Corporations Act (2001) (**Act**), the Company gives notice that:

• The Company issued 2,602,758 Shares between 17 and 19 July 2024 without disclosure to investors under Part 6D.2 of the Act.

• As at the date of this notice, the Company has complied with:

- the provisions of Chapter 2M of the Act as they apply to the Company; and
- sections 674 and 674A of the Act.

• As at the date of this notice there is no information that is 'excluded information' (as defined in sections 708A(7) and 708A(8) of the Act) which is required to be disclosed by the Company.

This ASX announcement was approved and authorised for release by the Board.

- End -

Investor Contact: **Media Contact:**
Dr Chris Burns   H^CK Director, Haley Chartres
Chief Executive Officer   haley@hck.digital
chris@ampliatx.com   +61 423 139 163

About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn.

Level 17, 350 Queen Street, Melbourne VIC 3000
Email info@ampliatx.com
www.ampliatx.com